Libtayo® (cemiplimab-rwlc)
for Lung Cancer

Libtayo (cemiplimab-rwlc) is an immunotherapy used to treat certain skin and lung cancers. It treats advanced cutaneous squamous cell carcinoma (CSCC), and basal cell carcinoma (BCC) when surgery or radiation isn’t an option or after hedgehog pathway inhibitor (HHI) treatment. It also treats non-small cell lung cancer (NSCLC) in locally advanced or metastatic cases without EGFR, ALK, or ROS1 mutations, used alone or with platinum-based chemotherapy.

Heart